Systems and methods for predicting homologous recombination deficiency status of a specimen

Methods, systems, and software are provided for an ensemble model trained to distinguish between cancers with homologous recombination pathway deficiencies (HRD positive cancers) and cancers without homologous recombination pathway deficiencies (HRD negative cancers) based on nucleic acid sequencing...

Full description

Saved in:
Bibliographic Details
Main Authors LEIBOWITZ, Benjamin, IGARTUA, Catherine, BELL, Joshua S.K
Format Patent
LanguageEnglish
Published 16.06.2022
Subjects
INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS
PHYSICS
Online AccessGet full text

Cover

More Information
Summary:Methods, systems, and software are provided for an ensemble model trained to distinguish between cancers with homologous recombination pathway deficiencies (HRD positive cancers) and cancers without homologous recombination pathway deficiencies (HRD negative cancers) based on nucleic acid sequencing data, e.g., both RNA and DNA sequencing data, generated from a cancerous tissue sample of the subject.
Bibliography:Application Number: AU20200398913